Načítá se...
Monitoring minimal residual disease in the bone marrow using next generation sequencing
Achieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencin...
Uloženo v:
| Vydáno v: | Best Pract Res Clin Haematol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7133460/ https://ncbi.nlm.nih.gov/pubmed/32139014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2020.101149 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|